These results together suggest that high levels of THY1 and complement components in T1 tumors provoke an immunosuppressive tumor microenvironment, suggesting an inflammatory phenotype, and open up the possibility of using a combination of immunotherapy coupled with anti-PD1/PD-L1 therapy in patients with these T1 tumors. The gene discussed is THY1; the disease is neoplasm.